CareDx has turned into a dramatic share price story, yet the real question for anyone looking at the stock today is whether that move is supported by the cash it can generate over time. After such a sharp shift in market expectations, the focus naturally swings to what the company’s cash flows suggest about an intrinsic value anchor.
- Over the past 3 years the stock has delivered a very large gain of about 8.8x, which puts a lot of pressure on the current valuation to be grounded in durable cash generation rather than sentiment.
- BTIG’s recent decision to lift its price target to US$74 after meetings with management points to higher expectations for the transplant testing and oncology pipelines, which can affect how quickly CareDx converts growth into cash and how much funding it may need along the way.
- What if you looked at CareDx through its earnings instead? See why CareDx's 29.7x P/E tells a different valuation story.
The issue now is whether the present share price near US$63.79 is justified by CareDx’s cash flows when assessed against an intrinsic value estimate built from its Discounted Cash Flow model.
If you want to test the same cash flow question that surrounds CareDx across a wider field, take a look at companies in the 27 high quality undervalued stocks
Is CareDx a Bargain on Cash Flow?
The Discounted Cash Flow model for CareDx starts with the cash the business can plausibly return to shareholders over time. On the latest numbers, CareDx is generating trailing twelve month free cash flow of about $83.9 million, and the valuation framework extends that stream forward using a 2 Stage Free Cash Flow to Equity approach with growing cash flows over the next decade.
Projected annual free cash flow in this DCF builds from that $83.9 million base toward higher levels by 2030 and beyond. This suggests that the current share price of $63.79 does not fully reflect the cash earnings power implied in the model. Because BTIG’s higher US$74 target followed renewed confidence in transplant testing and the oncology pipeline, that bullish research view aligns with a market price that still screens below what these cash flow projections support in the DCF. Find out what CareDx could be worth using our Discounted Cash Flow (DCF) estimate.
The CareDx Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the CareDx cash flow puzzle leaves off by explaining which paths for growth, profitability and earnings would need to unfold for the stock to look meaningfully higher or lower than today’s price on the numbers. Each storyline ties its implied value to a clear view of where CareDx's expansion, margins and key risks might head next, so you can refer back to those assumptions as new information becomes available.
CareDx has split the community, with one camp seeing Medicare clarity and new tech as upside while the other worries that execution and reimbursement keep a lid on value.
Bull case: 14% undervalued
"The expanded push into digital health software, remote patient monitoring, and data analytics leverages the ongoing transition toward value-based, preventive healthcare..."
Discover why this Narrative puts CareDx at 14% undervalued.
Bear case: 14% overvalued
"Introduction of bundled payments and frequency limits for surveillance testing under the new draft LCD policy could potentially result in an annual revenue headwind of $15-30 million..."
Explore why this Narrative puts CareDx at 14% overvalued.
One more piece of the CareDx puzzle before you act
Before you lean too hard on any cash flow model for CareDx, it helps to know who is steering the ship, how their incentives are wired, and whether those rewards truly match your interests. See who runs CareDx and how they are paid.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com